摘要
目的比较孟鲁司特与舒利迭联合治疗与单用舒利迭治疗重度哮喘的有效性。方法将60例成人慢性重症哮喘病例随机分成两组,分别使用孟鲁司特联合舒利迭及单用舒利迭治疗12周,在治疗前及治疗后观察肺功能和临床症状的改变。结果两组治疗前后第1秒用力呼气量(FEV1)改善率和FEV1占预计值的百分数均有显著提高(P<0.01)。在治疗后第8周,加用孟鲁司特组FEV1改善率和FEV1占预计值的百分数较舒利迭组的提高差异有显著性(P<0.05)。孟鲁司特与舒利迭联合治疗的临床症状评分明显优于单用舒利迭(P<0.01)。结论应用舒利迭同孟鲁司特联合治疗哮喘能更迅速改善临床症状和肺功能,提示二者有一定的疗效相加作用。
[Objective] To compare the efficiency of Seretide plus Montelukast and Seretide only on patients with severe persistent asthma. [Methods] Sixty patients with severe persistent asthma were randomly divided into two groups treated with Seretide plus Montelukast and Seretide only for 12 weeks. The pulmonary function and clinical symptom before and after treatment were observed in two groups. [Results] The forced expiratory volume in 1 second （FEV1） after treatment improved significantly in the beth groups （P 〈0.01）. The improved rate of FEV1 and FEV 1% in the predicted value in the group plus Montelukast was significantly higher than that in the group without Montelukast at week 4 after treatment （P 〈0.05）. The symptom score in the group plus Montelukast were significantly lower than that in the group without Montelukast （P 〈0.01）. [Conclusion] The clinical improvement appears more rapidly in treatment by Seretide plus Montelukast than by Seretide only.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2008年第9期1294-1295,1298,共3页
China Journal of Modern Medicine
关键词
孟鲁司特
治疗
哮喘
Montelukast
treatment
asthma
